Remdesivir in pregnant women with moderate to severe coronavirus disease 2019 (COVID-19): a retrospective cohort study

• Published in: Clinical and experimental medicine 2023-11, Vol.23 (7), p.3709-3717
• Main Authors: Arbabzadeh, Taraneh, Masoumi Shahrbabak, Maryam, Pooransari, Parichehr, Khatuni, Mahdi, Mirzamoradi, Masoumeh, Saleh Gargari, Soraya, Naeiji, Zahra, Rahmati, Nayereh, Omidi, Samaneh, Ebrahimi Meimand, Faridadin
• Format: Article
• Language: English
• Subjects: Antiviral drugs; Clinical Practice; Clinical trials; Cohort analysis; Coronaviruses; COVID-19; Hematology; Internal Medicine; Medicine; Medicine & Public Health; Neonates; Oncology; Patients; Pre-eclampsia; Preeclampsia; Pregnancy; Pregnancy complications; Respiration; Womens health
• ISSN: 1591-9528; 1591-8890; 1591-9528
• DOI: 10.1007/s10238-023-01095-0

Data on the efficacy of remdesivir in Coronavirus Disease 2019 (COVID-19) are limited in pregnant patients since they have been excluded from clinical trials. We aimed to investigate some clinical outcomes following remdesivir administration in pregnancy. This was a retrospective cohort study conducted on pregnant women with moderate to severe COVID-19. The enrolled patients were divided into two groups with and without remdesivir treatment. The primary outcomes of this study were the length of hospital and intensive care unit stay; respiratory parameters of hospital day 7 including respiratory rate, oxygen saturation, and mode of oxygen support; discharge until days 7 and 14, and need for home oxygen therapy. Secondary outcomes included some maternal and neonatal consequences. Eighty-one pregnant women (57 in the remdesivir group and 24 in the non-remdesivir group) were included. The two study groups were comparable according to the baseline demographic and clinical characteristics. Of the respiratory outcomes, remdesivir was significantly associated with a reduced length of hospital stay ( p  = 0.021) and also with a lower level of oxygen requirement in patients on low-flow oxygen [odds ratio (OR) 3.669]. Among the maternal consequences, no patients in the remdesivir group developed preeclampsia but three patients (12.5%) experienced this complication in the non-remdesivir group ( p  = 0.024). Furthermore, in patients with moderate COVID-19, the percentage of emergency termination was significantly lower in remdesivir group (OR 2.46). Our results demonstrated some probable benefits of remdesivir in respiratory and also maternal outcomes. Further investigations with a larger sample size should confirm these results.